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Retinoblastoma (Rb) is a children's eye cancer affecting
1:20,000 young children. Approximately 40% of cases have a
genetic basis and 25-30% have a positive family history with
the tumour phenotype segregating as an autosomal dominant
mutation based on a single autosomal locus. Of the 70%
apparently sporadic cases a proportion (20-30%) represent
new germinal mutations. Although the Rb gene mutation
shows high penetrance approximately 10% of gene carriers
do not develop tumours ('incomplete penetrance') so clearly
only a predisposition to cancer is inherited. In a mathe-
matical treatise of Rb Knudson (1971) demonstrated that, in
hereditary cases, a single additional event was sufficient for
tumorigenesis (the 'two-hit' hypothesis), a theory which
accounts for the fact that tumours in these patients are
usually bilateral, multifocal and have an earlier age of onset
compared with sporadic cases which are most often unilateral
and unifocal. Mutations are defined as any disturbance of the
gene which results in loss of function and includes deletions,
translocations and point mutations. Early detection of
tumours means that survival is almost guaranteed, but once
the tumour has escaped the confines of the eye it is usually
lethal. Identification of gene carriers, therefore, is essential
for improved clinical management of the disease. The recent
molecular cloning of the Rb gene has proved invaluable in
establishing gene carrier status and also provides the oppor-
tunity to study early events in tumorigenesis.
Isolation of the RB gene
Following cytogenetic observations (Lele et al., 1963; Yunis
& Ramsay, 1978) and family linkage studies (Sparkes et al.,
1983) the RBI gene was assigned to chromosome region
13ql4. Cavenee et al. (1983) demonstrated that, in individ-
uals who were constitutionally heterozygous for chromosome
13 loci, their tumours were homo- or hemi-zygous at the
same loci. This 'loss of heterozygosity' was presumed to lead
to 'exposure' of the recessive disease causing mutation in the
Rb gene. In heterditary cases, only copies of the chromosome
carrying the mutant gene were retained in tumour cells
(Cavenee et al., 1985) thus providing formal proof of Knud-
son's hypothesis. Possible mechanisms for loss of the normal
allele included mitotic recombination and non-disjunction.
Since loss of RB1 function is required for tumorigenesis the
normal function of the gene appears to be to maintain
normal cellular growth control. This controlling function has
resulted in this class of cancer genes being called 'tumour
suppressor genes' or 'recessive cancer genes'. The majority of
human familial cancer predisposition syndromes fall into this
class.
Chromosome 13-specific DNA probes were isolated and
subregionally localised using panels of somatic cell hybrids
(Lalande et al., 1984; Dryja et al., 1986). One of these DNA
clones lay within a coding sequence and a candidate gene was
isolated (Friend et al., 1986; Lee et al., 1987; Fung et al.,
Received 24 September 1990.
1987). Structural abnormalities involving this gene were
observed in approximately 20% of tumours but, importantly,
they were confined to the genomic sequence of the candidate
RBI gene, excluding the possibility that adjacent genes were
involved. Predisposition to Rb can also result from the
inheritance of chromosome translocations. We (Mitchell &
Cowell, 1989) and others (Higgins et al., 1989) showed that,
in these rare cases, the translocation breakpoints interrupted
the RBI gene. These observations lent further support to the
authenticity of the gene since the predisposing mutations in
these patients were confined to RB1. It has since been shown
(see below) that more subtle mutations occur in the majority
of tumours.
Mutations in the Rb gene
The Rb gene is large, spanning 200 kb of genomic DNA, is
divided into 27 relatively small exons with two large (>50
kb) introns (Friend et al., 1987; Bookstein et al., 1988) and
produces an mRNA 4.7 kb long. The exon/intron structure
of the gene has been characterised (McGee et al., 1989) and
the amino acid sequence of the gene product determined.
Despite this information there are no common motifs to
indicate its function.
In the majority of tumours there is loss of heterozygosity
for the 13q14 region (Zhu et al., 1989) and therefore,
presumably homozygosity for the specific predisposing muta-
tion. In some cases, however, tumorigenesis will result from
independent mutations in the two homologous genes. In the
UK, however, the majority of tumours are treated in situ
using cryosurgery or radiotherapy which makes obtaining
tumour tissue difficult. Those researchers who have been able
to perform extensive analysis of the RNA from tumours have
usually had the foresight to develop cell lines in vitro (Gallie
et al., 1982). Even when tumour material is available an
mRNA may not be produced or there may not be sufficient
viable cells to make. Despite these limitations Dunn and
colleagues (1988, 1989) have identified mutations in tumour
cells using RNAase protection techniques which is a means
of detecting mismatches between tumour RNA and the nor-
mal sequence. Point mutations, splice junction mutations,
and small deletions could all be detected. Although more
than 20 tumours were analysed, however, no single region of
the gene was preferentially involved. To overcome problems
associated with RNA analysis Yandell et al. (1989) analysed
the DNA sequence of RBI in tumour cells exon-by-exon.
The availability of the normal 250 base pair sequence on
either side of each exon (McGee et al., 1989) meant that
specific oligonucleotides could be designed and each exon/
intron region amplified using the polymerase-chain-reaction
(PCR). The amplified product was then sequenced and muta-
tions were identified by comparison with the normal sequence
in seven tumours. If the same mutation was present in nor-
mal constitutional cells from the same patient that individual
was identified as a gene carrier. This analysis also identified
mutations such as premature stop codons in the flanking
intron region which would not have been found in the RNA
transcript.
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Genetic screening
Until recently, since the appearance of tumours was the only
way ofidentifying gene carriers in families, genetic screening
has taken the form of frequent ophthalmological examina-
tion, under anaesthetic, of all children of affected individuals
frequently up to the age of five and less frequently until the
age of 11. Because 10% of gene carriers will be unaffected
the cousins of affected individuals are also screened.
Although all multifocal, bilaterally affected individuals must
be considered gene carriers, occasionally unifocally affected
individuals also have affected children (Cowell et al., 1987).
We have noted in our series (Cowell et al., 1987; Onadim et
al., 1990) that these 'milder' phenotypes often cluster in
families and may reflect a distinct class ofpredisposing muta-
tions. In practise, therefore, all relatives of affected patients
are potentially at risk and are screened. Another feature of
apparently unaffected gene carriers is that they may have
retinal scars which either represent a benign form of the
disease, retinomas (Gallie et al., 1982), or, since they resem-
ble successfully treated tumours, may be the result of spon-
taneous regression. Individuals with a prior family history
and retinal scars are gene carriers which underlines the
importance of full ophthalmological examination of relatives
of affected children.
The isolation of RB1 has already had a significant impact
on the genetic counselling advice available to Rb patients.
Using the RB gene in linkage analysis makes the frequency
of recombination between probe and phenotype minimal,
although it could not be used directly because the 4.7 kb
cDNA does not identify polymorphic restriction enzyme
sites. Instead Wiggs et al. (1988) isolated a variety of unique
sequence DNA probes from within the genomic sequence
which allowed standard linkage analysis (Wiggs et al., 1988;
Onadim et al., 1990; Scheffer et al., 1989) using restriction
fragment length polymorphisms (RFLPs). Approximately
85% of families can now be offered prenatal screening and
carrier detection using these probes alone (Onadim et al.,
1990) and no recombinants have yet been demonstrated. We
have reported the application of RFLP analysis to prenatal
screening using chorionic villus sampling of 8-10 week
fetuses (Mitchell et al., 1988; Onadim et al., 1990).
Excluding individuals as gene carriers is actually as impor-
tant as identifying 'at risk' patients since they will no longer
need to undergo frequent, labour intensive, expensive,
ophthalmological examinations. In practise most individuals
currently undergoing screening will be spared this procedure.
For the 15-20% of patients who are homozygous at all of
the polymorphic sites new techniques have been developed.
McGee et al. (1989) reported a 4-base pair variable number
tandem repeat in the intron flanking exon 20. It is estimated
that greater than 90% of individuals are heterozygous at this
locus. Since the allele sizes in different individuals may differ
by as little as a single base pair, however, the procedure is
not as straightforward as conventional Southern blot analy-
sis. The same group (Yandell & Dryja, 1989) also reported a
naturally-occurring single base pair polymorphisms in RB1
which can only be detected following sequencing.
Where genetic linkage studies are not feasible, either
because key family members are unobtainable or transmitting
individuals are homozygous at all loci, direct analysis of gene
mutations is critical. This is especially true for those sporadic
cases that may represent new germinal mutations. PCR-
sequencing of the RB 1 exons is more straightforward in
tumours which are homozygous for the predisposing muta-
tion. Mutations identified in tumours which are also shown
to be present in constitutional normal cells identifies that
patient as a gene carrier. Clearly it is desirable, therefore, to
obtain tumour tissue if possible. Formalin-fixed paraffin- embedded tissue can now be used as a source of DNA for
PCR-sequencing analysis which means that retrospective analysis of archival material is now also possible. If no
tumour tissue is available, constitutional cells can be analysed using PCR-sequencing but the procedure is complicated by the presence of the normal allele. A random PCR-sequencing
analysis of the 27 exons of RB1 is very laborious, and a way
of pre-screening the exons is needed to identify those most
likely to carry mutations. A variety of techniques whieh rely
on base pair mismatch analysis of heterozygotes will
undoubtedly improve efficiency. The limitations are, however,
that not all of the gene is 'seen' by PCR-sequencing and
failure to find a mutation may not exclude gene carrier
status. The PCR-sequencing technology can also be applied
to mRNA from tumours and requires less material than for
RNAase protection.
For families showing incomplete penetrance traditional
linkage studies will allow for unequivocal identification of
unaffected gene carriers. Incomplete penetrance can also
manifest in families where several affected individuals are
born to unaffected parents. Again genetic predisposition is
probable. In this case either one parent is an unaffected gene
carrier or is a gonadal mosaic, carrying the predisposing
mutation in the germ line but not the retina. Characterising
the predisposing mutation in these cases may not identify the
transmitting parent but offers a means of screening subse-
quent pregnancies. In some cases unusual pedigrees showing
evidence ofincomplete penetrance may be due to the segrega-
tion of unbalanced chromosome rearrangements. It is advis-
able therefore to analyse the karyotypes of constitutional
cells in these families.
Linkage analysis using the adjacent esterase-D gene
(Cowell et al., 1987) has now been superseded by the use of
intragenic DNA probes. It is still worthwhile, however,
measuring ESD levels in Rb patients to identify those 3% of
cases (Cowell et al., 1989) carrying constitutional chromo-
some deletions (13q-). Larger deletions are more easily iden-
tified since they are usually associated with other congenital
abnormalities. In our series, however, at least half of 13q-
patients had only small deletions and few dysmorphic
features. These deletions can be transmitted from parent to
child (Cowell et al., 1988). Currently 50% of 13q- patients
are only unilaterally affected which is unrelated to the size of
the deletion. This finding apparently contradicts the predic-
tion that predisposed individuals will develop multifocal,
bilateral tumours. One explanation is that other mutations
within the deletion are lethal and potential tumour precursor
cells fail to proliferate. This explanation presumably accounts
for reports of 13q- patients who have not developed retino-
blastoma (Cowell et al., 1988; Wilson et al., 1987).
The RB gene product
Some RB1 mutations result in abnormal transcripts or the
absence of transcripts (Lee et al., 1987; Fung et al., 1987),
whereas other tumours produce apparently normal mRNA
(Goddard et al., 1988). The use of monoclonal antibodies to
the RBI protein (pRB) however, demonstrated that, in the
majority of cases, even if an mRNA is produced in tumour
cells pRB is not (Whyte et al., 1988; Horowitz et al., 1990).
That pRB is apparently confined to the nucleus and binds to
DNA (Lee et al., 1987) suggests that it is a regulatory
protein. However, it is expressed in a wide variety of cells, in
addition to developing retinal cells.
Addition of certain growth factors to quiescent cells causes
them to divide. The RB1 gene must be inactivated for tumo-
rigenesis. Does RB, therefore, restrict cell proliferation? pRB
exists in phosphorylated and unphosphoryated forms, the
phosphorylated form appearing in the GI stage of the cell
cycle and declines after S phase suggesting a role in cell
division (Mihara et al., 1989). Cells induced to terminally
differentiate (thereby losing their proliferative potential) also
lose their ability to phosphorylate pRB. The only indication
of how pRB functions biochemically to regulate cell growth
follows the observation that it binds to the transforming
proteins ofcertain DNA viruses. These proteins can over-ride
the normal growth regulations of the cell. Thus, pRB binds
to Ela of adenovirus (Whyte et al., 1988), large-T antigen of
SV40 (Ludlow et al., 1989), and E7 of human papilloma
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pRB and it is the unphosphorylated form which is targetted
(Ludlow et al., 1989). These observations imply that, by
maintaining pRB in the unphosphorylated form, cells stay
quiescent. Phosphorylating or inactivating pRB pushes the
cells through mitosis which is required by the DNA viruses
for self-replication. Whilst providing an opportunity to study
the control of the cell cycle it is still not clear, however, how
this gene functions to induce differentiation in primitive
retinal cells. Although the position of naturally occurring
mutations within the gene is apparently random, those pre-
venting Ela binding apparently cluster in the 10-12 exons
flanking the large central intron (Hu et al., 1990). There have
been too few reports to date, however, to draw any definite
conclusions as to the significance of this observation.
Second tumours
Individuals predisposed to Rb are also at a significantly
higher risk than the general population to the development
of second, non-ocular tumours especially osterosarcoma and
soft tissue sarcomas (Abramson et al., 1984; Draper et al.,
1986). These tumours may arise in the radiation treatment
field, but also occur both in unirradiated sites and in patients
who have not received radiation at all. In these tumours the
RB1 gene shows frequent structural abnormalities (Togu-
chida et al., 1988; Friend et al., 1987) implicating it in
pathogenesis. Abnormalities of RBI have also been detected
in tumours not associated with Rb predisposition including
bladder cancer (Horowitz et al., 1989), small cell lung car-
cinoma (Harbour et al., 1988) and breast cancer (Lee et al.,
1988). Abnormalties in these tumours, however, are infre-
quent and more likely reflect tumour progression than
tumour initiation.
Suppression ofmalignancy by RB1
If functional inactivation of both copies of RB1 is a pre-
requisite for tumorigenesis, the introduciton of a normal gene
should restore the normal phenotype. Huang et al. (1988)
reported that introducing RB1 via a retroviral vector chang-
ed the in vitro phenotype of one Rb cell line with a
homozygous deletion of RB1. These cells assumed charac-
teristics suggesting differentiation and, unlike the parental
cell line failed to produce tumours in nude mice. The same
was also true in an osteosarcoma cell line deficient in RB1
function. Surprisingly the tumorigenicity in a prostate cancer
cell line was also suppressed after introduction of the
retrovirus-linked gene (Bookstein et al., 1990). Clearly, to
understand the function of RB1 in retinal development an
animal model would be desirable, but to date none exists.
The creation oftransgenic mice that develop Rb-like tumours
following introduction of the SV40 genome is noteworthy.
However the integration site is on chromosome 4 and not
chromosome 14 which is the site of the endogenous mouse
RBI gene (Windle et al., 1990).
Future prospects
The cloning of the retinoblastoma gene is already having a
major influence on the clinical management of the disease.
Soon unequivocal identification of all gene carriers in Rb
families will be possible and, thereby, allow resources to be
concentrated on those patients who need them. Direct ana-
lysis of the RBI gene sequence, as described, will eventually
allow us to determine whether new patients represent spora-
dic cases or carry germ-line mutations. The identification of
specific predisposing mutations in individuals will also un-
doubtedly improve our understanding of gene function. As
more data accumulates and patterns emerge it may be that
molecular pathology will be able to predict the course of this
disease in terms of invasiveness/prognosis, whether bilateral,
unilateral or regressed tumours will arise and whether
patients will be susceptible to second tumours. Unravelling
the intricate way in which this gene controls the development
of several different tissues and its influence on the cell cycle,
however, is still in the very early stages.
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